Tanabe Seiyaku launched Methotrexate tablets 2mg TANABE (generic name: methotrexate), an anti-rheumatic drug for the indication of rheumatoid arthritis (RA) only if there is no indication of improvement when conventional treatment therapies such as nonsteroidal anti-inflammatory agents and other anti-rheumatic agents are used, on July 21.
Tanabe has already marketed Remicade, an anti-human TNF-alpha monoclonal antibody drug that has shown high efficacy in treating over 10,000 patients. When used in combination with Methotrexate, Remicade achieves the maximum clinical effect by stopping joint destruction.
Tanabe speculates that the launch of Methotrexate will accelerate the use of Remicade in the future.
By Aki Tsukioka, JCN Staff Writer
Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.
JCN
View drug information on Remicade.
Комментариев нет:
Отправить комментарий